PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
Recurrent Langerhans Cell Histiocytosis
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Recurrent Langerhans Cell Histiocytosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
Palbociclib National Cancer Institute (NCI) | Phase 2 | B |
Tazemetostat National Cancer Institute (NCI) | Phase 2 | B |
PI3K/MTOR INHIBITOR LY3023414 National Cancer Institute (NCI) | Phase 2 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
View all 10 →
Same molecule, other indications
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →